Gynecologic Oncology | Interview with David O’Malley, MD

Data + Perspectives: The Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in the Management of Gynecologic Cancers — Interview with Dr O’Malley on the following topics: Emerging efficacy and safety data with and ongoing investigation of tisotumab vedotin in the management of gynecologic cancers (00:00) Dual ICI combination regimens under investigation for gynecologic cancers (3:50) Clinical care of patients with HER2-positive endometrial cancer (8:39) Efficacy and tolerability of pembrolizumab/lenvatinib in patients with microsatellite-stable endometrial cancer (12:01) CME information and select publications